Acer Therapeutics Inc (ACER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Acer Therapeutics Inc (Acer), formerly Opexa Therapeutics Inc is a pharmaceutical company that offers acquisition, development and commercialization of therapies for patients with serious rare diseases. The company offers treatment of autoimmune disorders, rheumatoid arthritis, diabetes and heart failure. Its late-stage clinical pipeline includes drug candidates for severe genetic disorders such as EDSIVO and celiprolol for vascular Ehlers-Danlos syndrome, and ACER-001, a fully taste-masked, immediate release formulation of sodium phenylbutyrate for urea cycle disorders. It uses T-cell technology platform for the development of patient-specific T-cell therapies. The company operates manufacturing facility, and research and development facilities in the US and Canada. Acer is headquartered in Newton, Massachusetts, the US.

Acer Therapeutics Inc (ACER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acer Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acer Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Acer Therapeutics Raises USD15.7 Million in Venture Financing 12
Acer Therapeutics to Raise USD10 Million in Venture Financing 13
Acer Therapeutics Raises USD8.2 Million in Financing 14
Acer Therapeutics Raises USD2 Million in Venture Financing 15
Licensing Agreements 16
Acer Therapeutics Enters into Licensing Agreement with AP-HP 16
Acer Therapeutics Enters into Licensing Agreement with Baylor College of Medicine 17
Equity Offering 18
Acer Therapeutics Raises USD46 Million in Public Offering of Shares 18
Acer Therapeutics Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares for USD12.6 Million 20
Opexa Therapeutics Plans to Raise Funds through Public Offering of Shares 22
Opexa Therapeutics Raises USD0.5 Million in First Tranche of Private Placement of Shares 23
Opexa Therapeutics Raises USD13.8 Million in Rights Offering of Units 25
Opexa Therapeutics Completes Public Offering Of Shares For US$8 Million 27
Opexa Therapeutics Completes Underwriters Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$19 Million 29
Opexa Therapeutics Completes Private Placement Of Shares For US$0.5 Million 30
Opexa Therapeutics Completes Private Placement Of Units For US$3.2 Million 31
Opexa Therapeutics Private Placement Of Common Stock For US$0.5 Million 33
Opexa Therapeutics Files Prospectus For Public Offering Of Shares 34
Opexa Therapeutics Completes First Tranche Of Private Placement Of Shares For US$0.05 Million 35
Debt Offering 37
Opexa Therapeutics Raises USD4.1 Million in Private Placement of Notes 37
Acquisition 38
Opexa Therapeutics Acquires Acer Therapeutics in Reverse Takeover Transaction 38
Acer Therapeutics Inc - Key Competitors 39
Acer Therapeutics Inc - Key Employees 40
Acer Therapeutics Inc - Locations And Subsidiaries 41
Head Office 41
Recent Developments 42
Financial Announcements 42
Aug 13, 2018: Acer Therapeutics reports second quarter 2018 financial results and provides corporate update 42
May 14, 2018: Acer Therapeutics Announces First Quarter 2018 Financial Results 44
Mar 07, 2018: Acer Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 45
Nov 13, 2017: Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 47
Corporate Communications 48
Oct 12, 2017: Acer Therapeutics Welcomes Two New Members to its Board of Directors 48
Oct 05, 2017: Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer 49
Product Approvals 50
Sep 25, 2017: Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List Of Tables


Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acer Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acer Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acer Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acer Therapeutics Raises USD15.7 Million in Venture Financing 12
Acer Therapeutics to Raise USD10 Million in Venture Financing 13
Acer Therapeutics Raises USD8.2 Million in Financing 14
Acer Therapeutics Raises USD2 Million in Venture Financing 15
Acer Therapeutics Enters into Licensing Agreement with AP-HP 16
Acer Therapeutics Enters into Licensing Agreement with Baylor College of Medicine 17
Acer Therapeutics Raises USD46 Million in Public Offering of Shares 18
Acer Therapeutics Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares for USD12.6 Million 20
Opexa Therapeutics Plans to Raise Funds through Public Offering of Shares 22
Opexa Therapeutics Raises USD0.5 Million in First Tranche of Private Placement of Shares 23
Opexa Therapeutics Raises USD13.8 Million in Rights Offering of Units 25
Opexa Therapeutics Completes Public Offering Of Shares For US$8 Million 27
Opexa Therapeutics Completes Underwriters Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$19 Million 29
Opexa Therapeutics Completes Private Placement Of Shares For US$0.5 Million 30
Opexa Therapeutics Completes Private Placement Of Units For US$3.2 Million 31
Opexa Therapeutics Private Placement Of Common Stock For US$0.5 Million 33
Opexa Therapeutics Files Prospectus For Public Offering Of Shares 34
Opexa Therapeutics Completes First Tranche Of Private Placement Of Shares For US$0.05 Million 35
Opexa Therapeutics Raises USD4.1 Million in Private Placement of Notes 37
Opexa Therapeutics Acquires Acer Therapeutics in Reverse Takeover Transaction 38
Acer Therapeutics Inc, Key Competitors 39
Acer Therapeutics Inc, Key Employees 40

List Of Figures


Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acer Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Acer Therapeutics Inc (ACER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acer Therapeutics Inc (Acer), formerly Opexa Therapeutics Inc is a pharmaceutical company that offers acquisition, development and commercialization of therapies for patients with serious rare diseases. The company offers treatment

USD 250 View Report

Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets and distributes novel innovative branded products. It focuses on providing mens and womens health. The company uses its proprietary

USD 250 View Report

Anika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2019 Update

Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products

USD 750 View Report

Pear Therapeutics Inc - Product Pipeline Analysis, 2019 Update

Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD)

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available